Lv3
210 积分 2025-05-23 加入
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
4小时前
待确认
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
4天前
已关闭
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
4天前
已关闭
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
5天前
已完结
Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia
19天前
已完结
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
20天前
已完结
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial
27天前
已完结
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
1个月前
已完结
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
2个月前
已完结
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
